Studies and Registries

Access the latest studies, insights, and literature to improve care.

Expertise and clinical evidence

The introduction of new extracorporeal therapies for critically ill patients requires rigorous medical and scientific effort to demonstrate safety, efficacy, and clinical outcome benefits. This foundation is essential for the proper application, acceptance, and recommendation of the therapy as a standard adjunctive treatment, and for securing reimbursement within healthcare systems.

Because of this, we are continually expanding and enhancing the knowledge and clinical evidence supporting our therapies, making this information widely available to our clinical application partners.

Multicentric Studies

CytoSorbents has initiated numerous multicentric trials in cardiac surgery, septic shock, and critical care. Published studies validate CytoSorb’s safety and efficacy. Ongoing investigator-initiated trials, some actively recruiting and others completed, continue to confirm its effectiveness. Among others, projects in shock reversal in vasoplegic septic shock (PROCYSS study) and left-ventricular assist device implantation are underway. The STAR-T trial in the USA has now completed. An increase in published clinical data is expected, as several projects are nearing completion or already completed.

CytoSorbents study ID	Category	Country	Site	Patient No.	Status	Registration
S18	PROCYSS study	Germany	20	260	Recruiting	Resource
O06	COSMOS Registry	International	Multiple	3000	Recruiting	Resource
P01	Pancreatitis	Germany	Technical University Munich, Hospital Weiden	30	Published	Resource
CSI01	Cardiopulmonary bypass intraoperative (infective endocarditis / REMOVE)	Germany	14 sites	250	Published	Resource
CT Reg	COVID-19 CTC Registry	USA	Multiple	100	Published	Resource
S14	Septic Shock (MiHaS)	Germany	3 sites	40	Data analysis	Resource
CSI08	Cardiopulmonary bypass intraoperative	UK, Netherlands	2 sites	60	Recruiting	Resource
STAR	Antithrombotic removal registry	International	Multiple	500	Recruiting	Resource
STAR-T	Cardiopulmonary bypass intraoperative	USA	Multiple	120	Data analysis	Resource

Monocenter Studies

Renowned clinics all over the globe are studying the effectiveness of CytoSorbents’ solutions in various hyperinflammatory conditions. Research spans high-risk cardiac surgery on bypass, refractory septic shock, burns, and liver failure. Numerous investigator-initiated trials are in progress, with some recruiting or completed. Ongoing and upcoming projects indicate a continued surge in published evidence on the effectiveness and clinical outcomes of CytoSorb Therapy.

CytoSorbents study ID	Category	Country	Site	Patient No.	Status	Registration
Tx04	Orthotopic Heart Transplantation	Hungary	Semmelweis University, Budapest	60	Published	Resource
SepsAR3	Septic Shock	Netherlands	University Medical Centre, Mainz	150	Recruiting	Resource
S21	Septic Shock	Netherlands	Nijmegen Radboud UMC	24	Published	Resource
S19	Septic Shock	Germany	Hamburg University Hospital Hamburg-Eppendorf, Hamburg	32	Recruiting	Resource
O930	VA ECMO (cardiogenic shock)	Germany	Jena University Hospital	54	Recruiting	Resource
O921	COVID-19	Belgium	CHU Brugmann, Brussels	24	Data analysis	Resource
O03	Cytokine Release Syndrome	Germany	Hannover Medical School	34	Recruiting	Resource
EC05	Post arrest requiring eCPR	Germany	Freiburg University Hospital, Freiburg	20	Published	Resource
CYTOCOV-19	COVID-19 patients	Germany	Hamburg University Hospital Hamburg – Eppendorf, Hamburg	24	Published	Resource
Cyto-HOPE	Liver Transplant	Italy	Papa Giovanni XXIII Hospital, Bergamo	20	Recruiting	Resource
CSI26	Cardiac Surgery	Netherlands	LUMC Leiden	36	Recruiting	Resource
CSI22	Cardiac Surgery	Sweden	Sahlgrenska University Hospital Gothenburg	20	Published	Resource
CSI16	Cardiac Surgery	Switzerland	Dept of Intensive Care Medicine, Bern	54	Recruiting	Resource
CSI06	Cardiopulmonary bypass intraoperative	Germany	Nuremberg hospital	40	Publication phase	Resource
CGS01	Post cardiac arrest	Switzerland	Centre Hospitalier Universitaire, Vaudois, Lausanne	40	Published	Resource

The CytoSorb Registries

The COSMOS (CytoSorb TreatMent OF Critically Ill PatientS) registry was opened in mid-2022 and is a company-sponsored international registry designed to provide an infrastructure for the ongoing surveillance of CytoSorb use in real-world critical-care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient selection for CytoSorb and related treatment modalities. Recruitment is ongoing.

The STAR (Safe and Timely Antithrombotic Removal) registry was first registered with ClinicalTrials.gov in Sept 2021 and is a company sponsored multicentric European Registry designed to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents. Recruitment is ongoing.